Navigation Links
Study shows antibiotic improves respiratory function in lung transplant patients
Date:5/23/2012

ATS 2012, SAN FRANCISCO Researchers in the United Kingdom have determined that azithromycin, a broad-spectrum antibiotic that also has anti-inflammatory properties, can be an effective treatment option for patients suffering from bronchiolitis obliterans syndrome (BOS), a life-threatening complication that occurs in the majority of patients following lung transplantation.

BOS is the leading cause of mortality after the first year following transplantation, and occurs in part when the body repeatedly rejects the transplanted lung tissue. The syndrome causes the airways to become narrow and obstructed, resulting in a progressive decline in lung function and, eventually, respiratory failure. The exact full causes of the syndrome are unknown.

The study will be presented at the ATS 2012 International Conference in San Francisco.

The researchers evaluated the potential benefits of azithromycin, a type of antibiotic known as a macrolide, which works by inhibiting the ability of infection-causing bacteria to divide and replicate.

"In open studies, we and others have noted an improvement in lung function in BOS patients treated with macrolide antibiotics," said study lead author Paul Corris, professor of thoracic medicine at Newcastle University. "Other studies have not observed lung function gain with macrolide therapy, and there have been no randomized trials to date in patients with BOS."

"In this randomized study, we wanted to determine if patients treated with the antibiotic had improved lung function compared to patients who were treated with placebo," he said.

For their study, the researchers recruited 46 lung transplant patients with BOS and randomized them to receive either azithromycin (250mg on alternate days)or placebo. During the course of the study, 13 patients either withdrew or were withdrawn from the study; data from those individuals were included in a separate intent-to-treat (ITT) report.

To measure respiratory function, the researchers used a common lung function measurement called FEV1 (forced expiratory volume in the first second), which measures the volume of air (in millimeters, or ml) that can be forcibly exhaled in one second after taking a deep breath. By comparing patients' FEV1 values at the beginning of the study to FEV1 measurements made during the 12-week follow-up period, the researchers were able to determine if the patients' lung function had improved after being treated with azithromycin.

At the conclusion of their study, the researchers found that the patients who completed the study had a significant improvement in FEV1, with a mean difference of 358ml from baseline to 12 weeks; by comparison, patients in the placebo group experienced declines in their FEV1 measurements.

"Our randomized trial has confirmed that azithromycin improves lung function in patients with BOS following lung transplantation and this translates to improved survival for such patients," Dr. Corris noted. "There are ongoing studies trying to elucidate how the drug works which may well give clues to other potentially effective therapies."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
Breaking Medicine Technology: